Biosimilars Expected to Take Toll on Amgen

Document Sample
Biosimilars Expected to Take Toll on Amgen Powered By Docstoc
					Biosimilars Expected to Take Toll on Amgen
Biosimilar competition to multiple drugs is expected to reduce Amgens sales by
nearly US$ 9 Billion during 2013-2020

IMARC Group has recently released a new study suggesting that biosimilars will
erode a significant portion of Amgens sales during 2013-2020. According to the
report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A
Focus on the US (2011-2020)” four products from Amgen - Enbrel
(Ethanercept), Epogen (Epoetin Alfa), Neupogen (Filgrastim) and Neulasta
(Pegfilgrastim) are expected to face biosimilar competition during 2013-2020.
The study that has done a robust analysis on 21 biopharmaceuticals facing
biosimilar competition expects the combined sales of Amgens four drugs to
decline by US$ 9 Billion during 2011-2020.

IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report &
Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical
insight into the US biosimilar market. The study, that has been undertaken
using desk-based as well as qualitative primary research, provides and draws
upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

    Identification of currently marketed biosimilars and their historical
    Identifying the reasons for the slow uptake of currently marketed
    Analyzing historical data to formulate conclusions on the future growth
     and market trends of biosimilar

    Evaluating the Extent of Price, Sales and Volume Erosions Caused by

    Analyzing historical time series data on price, volume and sales erosion
     in the US & Europe
    Analyzing previous models and assumptions on price and volume
     erosion caused by biosimilars
    Evaluating and comparing price and volume erosion created by
     biosimilars vis-a-vis by small molecule generics
    Evaluating and comparing price, volume and sales erosion by biosimilars
     across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:

Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin
Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin
Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir),
Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B
(Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab
(Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab
(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab
(Xolair) and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

      Historical background and overview
      Historical brand sales
      Patent position
      Competing products
      Biosimilars in pipeline
      Brand and biosimilar sales forecast

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood
Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:

    Historical brand sales
    Brand and biosimilar sales forecasts
    Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:
    Identifying branded biological manufacturers that expect the highest
     amount of erosion from biosimilars
    Identifying biosimilar manufacturers and their pipelines

To obtain the complete report, please contact:


Phone: +91-120-425-6531

Europe, Middle East & Africa:

Phone: +44-702-409-7331

North & South America:

Phone: +1-631-791-1145

To know more please visit:


Biosimilar market, biosimilar industry, biogenerics market, us biosimilar market, biosimilar

monoclonal antibodies , follow-on biologics market,

Shared By: